Enovis Corp ENOV 深 滬
等待開盤 11-05 09:30:00 美东时间
24.28
+3.390
+16.23%
華盛通- 最 高24.61
- 今 開22.65
- 成交量 193.32万股
- 最 低 21.775
- 昨 收 20.89
- 總市值 14.00亿
- 52周最高 31.665
- 市盈率 靜 --
- 換手率 3.35%
- 52周最低 16.70
- 委 比 48.45%
- 總股本 5766.95万
- 歷史最高 176.11
- 量 比 1.73
- 振 幅 13.57%
- 歷史最低 -13.31
- 每 手 1
- 風險率 3.40%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 潜在涨幅386.16%！摩根士丹利维持TeraWulf"超配"评级，上调目标价至65美元
今日重点评级关注：摩根士丹利：维持TeraWulf"超配"评级，目标价从62.5美元升至65美元；摩根士丹利：维持Hut 8"超配"评级，目标价从273美元升至275美元
10-13 12:30
Needham Maintains Buy on Enovis, Lowers Price Target to $34
Needham analyst Mike Matson maintains Enovis (NYSE:ENOV) with a Buy and lowers the price target from $52 to $34.
10-12 18:12
Nyxoah names new CEO
Nyxoah (NYXH) appointed Liam Kelly as chief executive officer, effective October 1, 2026, succeeding Olivier Taelman. The leadership change comes as Nyxoah transitions toward a U.S.-focused commercial...
09-29 04:49
Nyxoah Appoints Liam Kelly as Chief Executive Officer
Nyxoah appoints Liam Kelly as Chief Executive Officer, effective October 1, 2026, to strengthen its U.S. presence following FDA approval and the launch of Genio. Kelly brings over 25 years of leadership experience, previously serving as CEO and Chairman of Teleflex Incorporated. Nyxoah focuses on developing innovative solutions for Obstructive Sleep Apnea (OSA), with Genio as its lead product. The appointment underscores the company's strategic s...
09-28 20:30
Enovis becomes first multi-registry industry sponsor of AAOS Registry Program
Company expands its support from the American Joint Replacement Registry to include the Shoulder & Elbow Registry ROSEMONT, Ill., Sept. 22, 2026 /PRNewswire/ -- The American Academy of Ortho...
09-23 00:02
美股周涨跌榜 | 生物医药企业SMMT周涨逾28%！关键药物取得突破；加密货币概念股齐升，IREN周内大涨26%
生物医药企业SMMT周涨逾28%！关键药物取得突破；加密货币概念股齐升，IREN周涨26%！受比特币反弹及云业务双重催化；Strive涨近25%，四天增持约1,800枚比特币>>
09-05 10:16
美股大行评级 | 最高735美元！戴尔科技绩后获11家大行上调目标价；MongoDB绩后分歧大，9家上调；4家下调；派拓网络、GitLab、美敦力获多家大行上调目标价
今日重点评级关注：Tigress Financial：维持Liftoff Mobile"买入"评级，目标价从39美元升至41美元；奥本海默：维持SpaceX"跑赢大市"评级，目标价从250美元升至280美元
09-03 13:50
Citizens Maintains Market Outperform on Enovis, Lowers Price Target to $47
Citizens analyst David Turkaly maintains Enovis (NYSE:ENOV) with a Market Outperform and lowers the price target from $55 to $47.
09-02 20:50
Enovis to acquire eCential Robotics
Enovis (ENOV) has agreed to acquire eCential Robotics for an upfront enterprise value of €155M. The deal corresponds to cash consideration of approximately €176M to be paid to eCential Robotics’ share...
09-01 19:02
Enovis Enters Into Binding Offer To Acquire eCential Robotics For Upfront Enterprise Value Of €155 Mln
Enhances Enovis’ enabling technology ecosystem to include robotic automation capabilities, empowering surgeons with a broader, integrated set of precision tools in the operating room. Creates a robotics center of excellence in Grenoble, France, a talent rich medical technology hub. Dallas, TX, Sep...
09-01 18:37
